Blog
RSS FeedPosted by Michael Wonder on 14 Apr 2022
ICER publishes 2022 research protocol for assessing unsupported price increases on prescription drugs
14 April 2022 - Final assessment to be published on 6 December 2022. ...
Posted by Michael Wonder on 07 Apr 2022
ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage
7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...
Posted by Michael Wonder on 16 Mar 2022
ICER publishes research protocol for assessing price increases of prescription drugs in California
16 March 2022 - Final assessment to be published on 13 October; drugs to be evaluated are those identified through California’s ...
Posted by Michael Wonder on 03 Mar 2022
ICER to develop a California state unsupported price increase report funded by the California Health Care Foundation
3 March 2022 - Expanded funding supports the development of two annual “Unsupported Price Increase” reports specific to drugs identified through ...
Posted by Michael Wonder on 10 Feb 2022
A new way to contain unaffordable medication costs - exercising the Government’s existing rights
9 February 2022 - Existing laws could be used to help make many drugs more affordable. ...
Posted by Michael Wonder on 01 Dec 2021
ICER publishes first annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
1 December 2021 - Scope of assessment limited by gaps in availability of payer policies and inability to evaluate how policies ...
Posted by Michael Wonder on 16 Nov 2021
ICER identifies most significant 2020 US drug price hikes not supported by new clinical evidence
16 November 2021 - Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of ...
Posted by Michael Wonder on 14 Sep 2021
Branded price variation in the United States drug market, 2010 to 2019
13 September 2021 - Branded drug prices command considerable attention in the United States yet defining a drug’s price is not ...
Posted by Michael Wonder on 31 May 2021
External reference pricing: the drug pricing reform America needs?
27 May 2021 - External reference pricing, sometimes known as international reference pricing, refers to the practice of informing price negotiations ...
Posted by Michael Wonder on 25 May 2021
ICER publishes protocol for first annual assessment of drug coverage policies that present barriers to fair access
25 May 2021 - ICER’s analysis, based on MMIT’s market access analytics solution, will evaluate how 15 of the largest ...
Posted by Michael Wonder on 12 Apr 2021
International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects
12 April 2021 - Many countries use international (or external) reference pricing—benchmarking prices against those in other countries—to manage spending ...
Posted by Michael Wonder on 12 Apr 2021
ICER publishes research protocol for assessing the unsupported price increases on prescription drugs that occurred in 2020
12 April 2021 - Final assessment to be published on 16 November; through 10 May, ICER is accepting public Input ...
Posted by Michael Wonder on 15 Feb 2021
Drug prices by committee: one way Biden could lower costs
11 February 2021 - Many countries use independent review boards to balance innovation and profit. ...
Posted by Michael Wonder on 12 Jan 2021
ICER identifies most significant 2019 US drug price hikes — even after rebates — that were not supported by new clinical evidence
12 January 2021 - Out of 10 identified drugs that had substantial 2019 price increases on top of already high current ...
Posted by Michael Wonder on 20 Oct 2020
Biden looks to Germany for answers on how to tackle high U.S. drug prices
20 October 2020 - With the U.S. election just two weeks away, Democratic presidential nominee Joe Biden is offering clues ...